Aim-To evaluate the validity ofthe colony forming unit-granulocyte macrophage (CFU-GM) assay for predicting relapse in patients with acute myeloid leukaemia (AML).
(AML).
Methods-The study population comprised 32 patients with AML in remission, followed for a median of 18 months. A mean of four studies was carried out per patient. Three patterns of in vitro growth based on the number of CFU-GM in normal bone marrow were defined: 1 = normal (normal number of CFU-GM and a cluster:colony ratio <2); 2 = hypoplastic (low number of CFU-GM and a cluster-:colony ratio <2); 3 = anomalous (low or normal number of CFU-GM and a cluster:colony ratio >2). Results-Eleven patients relapsed, all of whom had previously displayed an abnormal CFU-GM pattern: anomalous in nine and hypoplastic in two. The remaining 25 patients were in complete remission at the time of writing, 16 of whom had a normal growth pattern. The other nine had anomalous (eight patients) or hypoplastic (one patient) growth. The latter may be false positive results. The in vitro growth pattern was not constant during follow up analysis. All Accepted for publication 16 January 1996 centrifugation." The CFU-GM assay was carried as described by Iscove et al. ' 6 Briefly, 2 x 10' mononuclear cells/ml in Iscove's modified Dulbecco's medium (IMDM) were plated on 35 mm Petri dishes in 0.9% methylcellulose containing 10% phytohaemagglutinin stimulated leucocyte conditioned medium,"7 10% bovine serum albumin, and 10% human AB serum. Cultures were incubated at 37°C in a fully humidified atmosphere with 5% CO2 and scored on day 14 under an inverted microscope. Aggregates containing more than 40 cells were scored as colonies; aggregates containing four to 40 cells were scored as clusters.
Based on the CFU-GM pattern observed in normal bone marrow, we defined three patterns of in vitro growth: 1 = normal (normal number of CFU-GM and a cluster:colony ratio <2); 2 = hypoplastic (low number of CFU-GM and a cluster:colony ratio <2); 3 = anomalous (low or normal number of CFU-GM and a cluster:colony ratio >2). Normal values were (mean (SD)) 142 (60) CFU-GM and a cluster:colony ratio of 1.22 (0.18).
Results
Eleven patients relapsed, all of whom previously displayed an abnormal CFU-GM pattern: anomalous in nine and hypoplastic in two. No false negative results were observed. The median time between detection of an abnormal growth pattern and relapse was four + two months.
The remaining 25 patients were in complete remission at the time of writing: 16 had a normal CFU-GM growth pattern, whereas the other nine showed anomalous (eight patients) or hypoplastic (one patient) growth. These may be false positive results. Of the nine patients with an abnormal CFU-GM growth pattern, four also had other indicators of imminent relapse: in two patients the number of blast cells increased from undetectable levels by morphological and immunophenotypical methods to 1.3% and 4%, respectively; thrombocytopenia was diagnosed in the other two patients.
During the first three months of the study all except one patient had an abnormal CFU-GM growth pattern. Stable, normal CFU-GM growth patterns were observed a median of six months after diagnosis. All to assess residual haemopoietic damage as a result of treatment'9 but not for predicting relapse. Our results show that sequential investigation of the CFU-GM growth pattern may be helpful in predicting relapse in patients with AML. In our experience the proliferation pattern does not remain constant during the evolution of the disease and frequent changes may occur. All patients who achieved a normal growth pattern remain in complete remission, but a median of six months elapsed before a stable, normal growth pattern was observed. By contrast, three of the five patients whose initial normal growth pattern became abnormal relapsed. The other two patients exhibited other indicators of imminent relapse.'
Sequential studies of the CFU-GM growth pattern are mandatory if this technique is to be used to predict relapse. Thus, patients whose CFU-GM growth pattern changes from normal to abnormal must be monitored frequently as they are at a high risk of relapse. It is highly probable that those patients with a persistant, normal CFU-CM growth pattern of one years' duration will remain in remission and generally will not need further intensive treatment. A larger patient cohort and a longer follow up are needed to confirm these observations. 
